Oxybutynin is an antimuscarinic agent used for the treatment of overactive bladder (OAB) symptoms including urge urinary incontinence, urgency, and frequency. It is one of the oldest and most studied medications for OAB. Available in immediate-release, extended-release, transdermal patch, and topical gel formulations; extended-release and transdermal forms have improved tolerability compared to immediate-release.
Transdermal formulation reduces anticholinergic side effects7,8
What to watch for
Dry mouth (most common)
Constipation
Blurred vision
Urinary retention or significant bladder outlet obstruction3,6
Uncontrolled narrow-angle glaucoma
The bottom line
Evidence rating strong. Most-documented uses: reduces episodes of urge incontinence, decreases urinary urgency and frequency, multiple formulations for individualized therapy. 10 sources indexed (2001–2023), with 1 interaction record on file.
The science
How it works, mechanistically.
Core mechanism
Exerts direct antispasmodic effects on smooth muscle and inhibits the muscarinic action of acetylcholine on bladder smooth muscle (detrusor muscle). Specifically blocks M1 and M3 muscarinic receptors on the detrusor, reducing involuntary bladder contractions that cause urgency and incontinence. Also has local anesthetic and calcium channel blocking properties at higher concentrations.
Class
Anticholinergic / Overactive Bladder
Dosing
Dosing & protocol.
Common range
5 mg two to three times daily (immediate-release); 5-10 mg once daily (extended-release); 3.9 mg/day transdermal patch (applied twice weekly) (as prescribed by your physician)
Recommended form
Extended-release tablets (Ditropan XL) or transdermal patch/gel preferred to minimize dry mouth and other anticholinergic effects
Oral bioavailability ~6% due to extensive first-pass hepatic metabolism to active metabolite N-desethyloxybutynin (which causes most anticholinergic side effects). Extended-release and transdermal formulations bypass first-pass metabolism, producing lower N-DEO levels.
Safety
Full safety detail.
Side effects
Dry mouth (most common)
Constipation
Blurred vision
Somnolence and dizziness
Cognitive impairment (especially in elderly)
Urinary retention
Heat intolerance (decreased sweating)
Application site reactions (transdermal)
Contraindications
Urinary retention or significant bladder outlet obstruction3,6
Solid oral potassium chloride supplements can injure the upper gastrointestinal mucosa, and controlled endoscopy studies found more frequent or worse lesions when gastric motility was slowed with an anticholinergic. Oxybutynin is an antimuscarinic that can cause constipation and is contraindicated in gastric retention. The concern is greatest with wax-matrix or other solid potassium chloride products, high potassium doses, dehydration, or existing swallowing or GI motility problems.
Recommendation: Do not start solid potassium tablets or capsules while taking oxybutynin unless a clinician has recommended them and checked that they are necessary. If potassium is needed, ask whether liquid, powder-in-water, dietary potassium, or a monitored alternative is safer. Seek care for severe abdominal pain, black stools, vomiting blood, or painful swallowing.
El-Samahy M, Mouffokes A, Badawy MM et al.. Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. Archives of dermatological research. 2023
Shen SH, Jia X, Peng L et al.. Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis. International urology and nephrology. 2022
Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. American journal of obstetrics and gynecology. 2001
Aishah A, Loffler KA, Toson B et al.. One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial. Annals of the American Thoracic Society. 2023
Berger M, Solelhac G, Marchi NA et al.. Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial. Sleep. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Oxybutynin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack